Intra-Cellular Therapies Prices Public Offering of Common Stock
04 janv. 2022 22h05 HE
|
Intra-Cellular Therapies Inc.
NEW YORK, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
03 janv. 2022 16h01 HE
|
Intra-Cellular Therapies Inc.
NEW YORK, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies to Present at the 40th Annual J.P. Morgan Healthcare Conference
03 janv. 2022 08h00 HE
|
Intra-Cellular Therapies Inc.
NEW YORK, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies Announces U.S. FDA Approval of CAPLYTA® (lumateperone) for the Treatment of Bipolar Depression in Adults
20 déc. 2021 06h47 HE
|
Intra-Cellular Therapies Inc.
CAPLYTA is the only FDA-approved treatment for depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults as monotherapy and as adjunctive therapy with lithium or...
Intra-Cellular Therapies Mourns the Passing of Director, Dr. Richard Lerner
06 déc. 2021 16h01 HE
|
Intra-Cellular Therapies Inc.
NEW YORK, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies Reports Third Quarter 2021 Financial Results and Provides Corporate Update
09 nov. 2021 07h30 HE
|
Intra-Cellular Therapies Inc.
CAPLYTA supplemental new drug applications (sNDAs) for the treatment of bipolar depression are under review by the FDA, with a PDUFA target action date of December 17, 2021. Bipolar depression...
Intra-Cellular Therapies to Host Third Quarter 2021 Financial Results Conference Call and Webcast
02 nov. 2021 08h00 HE
|
Intra-Cellular Therapies Inc.
NEW YORK, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies Announces Amended Start Time to Virtual Event on Wednesday, October 20
18 oct. 2021 08h00 HE
|
Intra-Cellular Therapies Inc.
Webcast to begin at 1:00 p.m. ET Virtual event to include discussions on our lumateperone, ITI-1284, PDE1 inhibitors, and ITI-333 platforms NEW YORK, Oct. 18, 2021 (GLOBE NEWSWIRE) --...
Intra-Cellular Therapies to Host a Virtual Event to Feature Highlights of Several of its Development Programs
08 oct. 2021 08h00 HE
|
Intra-Cellular Therapies Inc.
Virtual event to include discussions on our lumateperone, ITI-1284, PDE1 inhibitors and ITI-333 platforms Webcast scheduled for Wednesday, Oct. 20 from 12:30 to 3:30 p.m. ET NEW YORK, Oct. 08, 2021...
Intra-Cellular Therapies Announces Publication of Lumateperone Pivotal Phase 3 Study in Bipolar Depression in The American Journal of Psychiatry
27 sept. 2021 07h30 HE
|
Intra-Cellular Therapies Inc.
In this study, lumateperone 42 mg showed significant reduction in depressive symptoms compared to placebo in patients with a major depressive episode associated with bipolar I or bipolar II disorder...